Pronai Therapeutics Inc., of Vancouver, British Columbia, said it obtained an exclusive license from Carna Biosciences Inc., of Kobe, Japan, for worldwide rights to develop and commercialize AS-141, a small-molecule kinase inhibitor targeting CDC7. Overexpression and activity of CDC7 is correlated with poor clinical outcomes and poor survival in a broad range of hematological malignancies and solid tumors.